Potent and selective N-type Ca2+ channel blocker (IC50 ~ 60 nM); selectively and reversibly blocks N-type Ca2+ channels. Does not block T-type Ca2+ channels, K+ channels or Na+ channels. Exhibits analgesic effects in vivo.
(Modifications: Disulfide bridge: 1-16,8-21,15-36)
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 1 mg/ml in water|
References are publications that support the biological activity of the product.
Deng et al (2014) Huwentoxin-XVI, an analgesic, highly reversible mammalian N-type calcium channel antagonist from Chinese tarantula Ornithoctonus huwena. Neuropharmacology 79 657 PMID: 24467846
Jiang et al (2010) Venomics of the spider Ornithoctonus huwena based on transcriptomic versus proteomic analysis. Comp.Biochem.Physiol.Part D Genomics Proteomics 5 81 PMID: 20403776
If you know of a relevant reference for Huwentoxin XVI, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Huwentoxin XVI, Huwentoxin XVI supplier, Huwentoxin, 16, Potent, selective, N, type, Ca2+, channel, blockers, reversible, analgesics, venoms, Voltage-gated, Calcium, Channels, 5235, Tocris Bioscience
Citations for Huwentoxin XVI
Citations are publications that use Tocris products.
Currently there are no citations for Huwentoxin XVI. Do you know of a great paper that uses Huwentoxin XVI from Tocris? Please let us know.
Reviews for Huwentoxin XVI
There are currently no reviews for this product. Be the first to review Huwentoxin XVI and earn rewards!
Have you used Huwentoxin XVI?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.